Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?

Cancer Cell

Volumn 4, Issue 1, 2003, Pages 13-18

  Johnstone, Ricky W ^a   Licht, Jonathan D ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; PHENYLBUTYRATE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CHROMATIN; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DISEASE COURSE; DNA BINDING; DRUG EFFECT; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; LYMPHOMA; METHYLATION; MYELODYSPLASTIC SYNDROME; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REVIEW; SILENCER GENE;

EID: 0041347519     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00165-X     Document Type: Review

References (30)

1. Archer S.Y., Meng S., Shei A., Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;6791-6796.
2. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., Shen T., Murphy T., Wickham J., Kanakry C.et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 102:2003;652-658.
3. Burgess A.J., Pavey S., Warrener R., Hunter L.J., Piva T.J., Musgrove E.A., Saunders N., Parsons P.G., Gabrielli B.G. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60:2001;828-837.
4. Chen Z., Clark S., Birkeland M., Sung C.M., Lago A., Liu R., Kirkpatrick R., Johanson K., Winkler J.D., Hu E. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 188:2002;127-140.
5. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., Jones P.A., Lubbert M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood. 100:2002;2957-2964.
6. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C.et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 295:2002;1079-1082.
7. Ferrara F.F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P.G., Lo Coco F., Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2001;2-7.
8. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors. Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2:2003;151-163.
9. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:2001;6969-6978.
10. Grozinger C.M., Schreiber S.L. Deacetylase enzymes. biological functions and the use of small-molecule inhibitors Chem. Biol. 9:2002;3-16.
11. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA. 100:2003;4389-4394.
12. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell R.P. Jr., Rifkind R.A., Marks P.A., Richon V.M., Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108:2001;1321-1330.
13. Henderson C., Mizzau M., Paroni G., Maestro R., Schneider C., Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. 278:2003;12579-12589.
14. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature. 417:2002;455-458.
15. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., Thiele C.J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62:2002;6108-6115.
16. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080.
17. Johnstone R.W. Histone-deacetylase inhibitors. novel drugs for the treatment of cancer Nat. Rev. Drug Discov. 1:2002;287-299.
18. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis. a link between cancer genetics and chemotherapy Cell. 108:2002;153-164.
19. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:2002;415-428.
20. Kelly W.K., O'Connor O.A., Marks P.A. Histone deacetylase inhibitors. from target to clinical trials Expert Opin. Investig. Drugs. 11:2002;1695-1713.
21. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2002;2383-2396.
22. Mariadason J.M., Corner G.A., Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids. comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer Cancer Res. 60:2000;4561-4572.
23. Melnick A., Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9:2002;322-332.
24. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T.et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 101:2003;4055-4062.
25. North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 11:2003;437-444.
26. Qiu L., Burgess A., Fairlie D.P., Leonard H., Parsons P.G., Gabrielli B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 11:2000;2069-2083.
27. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA. 97:2000;10014-10019.
28. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA. 98:2001;10833-10838.
29. Taddei A., Maison C., Roche D., Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 3:2001;114-120.
30. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., Sato F., Meltzer S.J., Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2:2002;485-495.